As a Global Biopharmaceutical Executive and CEO, I specialize in cultivating and steering successful entrepreneurial ventures with a steadfast dedication to advancing patient care. Experienced in both public and private markets, I lead commercial business units, corporate strategy, business development, and investor relations across diverse product lines and functions.With almost three decades in the biotech/pharma sector, I've introduced cutting-edge products to market targeting a range of medical conditions across autoimmune diseases. Among my significant achievements are the involvement in pre-launch activity for CellCept© (mycophenolate mofetil) and the launches of Remicade® (infliximab) and LUPKYNIS® across international markets with each making significant strides in improving patient outcomes.Remicade® notably holds the distinction of being the most successful product launch in Canadian history, a testament to its innovative approach and strategic execution. Additionally, I have been a key corporate leadership team member in the LUPKYNIS® NDA filing and approval processes , cementing its place as a groundbreaking therapeutic option for patients suffering from Lupus.Beyond product launches, I have navigated complex M&A activities, spearheaded intellectual property filing initiatives, and secured financing arrangements, from seed investments and PIPEs to fully marketed public cross-boarder transactions, ensuring the financial health and sustainability of the organization. My focus on operational budgeting and key performance metrics safeguards the robustness of operations and delivering on key performance metrics.As a dedicated Board Director, I am committed to advocating for and representing the interests of the life sciences community, fostering collaboration, and facilitating investment opportunities. Through strategic leadership and partnership cultivation, I actively contribute to the growth and advancement of our industry.